August 13, 2025 — Acrivon Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights. The company’s cash, cash equivalents, and marketable securities totaled $147.6 million as of June 30, 2025, which is expected to fund operations into the second quarter of 2027.
Acrivon is advancing two clinical-stage assets with clinically demonstrated single-agent anti-tumor activity: ACR-368 in a registrational-intent Phase 2 study in endometrial cancer, and ACR-2316 in a Phase 1 study in AP3-predicted tumor types. The company is utilizing its AI-driven AP3 Generative Phosphoproteomics platform for accelerated design and development of novel compounds like ACR-2316, based on optimal intracellular pathway selectivity.
Recent highlights include the continued advancement of the Phase 2b trial of ACR-368 in patients with recurrent high-grade endometrial cancer, and the initiation of a third arm to the Phase 2b study to evaluate ACR-368 with ultra low-dose gemcitabine (ULDG) in all-comer, biomarker-unselected 2nd line patients with endometrial cancer.
Enrollment continues in the Phase 1 monotherapy dose-escalation trial for ACR-2316 in certain high unmet need solid tumor types. Initial clinical activity has been observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer.
The company anticipates providing an update on the registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025, and reporting initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025.
For the quarter ended June 30, 2025, net loss was $21.0 million compared to $18.8 million for the same period in 2024. Research and development expenses were $16.2 million, compared to $15.0 million for the same period in 2024. General and administrative expenses were $6.5 million, consistent with $6.4 million for the same period in 2024.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
Source: Acrivon Therapeutics, Inc.
